The striatum and cerebral cortex express different muscarinic receptor mRNAs  by Brann, Mark R. et al.
Volume 230, number 1,2, 90-94 FEB 05698 March 1988 
The striatum and cerebral cortex express different muscarinic 
receptor mRNAs 
Mark R. Brann, Noel J. Buckley+ and Tom I. Banner+ 
Metabolic Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, Building 10, Room 9c-101 and 
+ Laboratory of Cell Biology, National Institute of Mental Health, Building 36, Room 3A-I 7, National Insitutes of Health, 
Bethesda, MD 20892, USA 
Received 1 February 1988 
The existence of four distinct muscarinic acetylcholine receptor genes (ml -m4) has recently been demonstrated. cDNAs 
for three of these receptors have been cloned from brain (ml, m3, m4) and one from heart (m2). To gain some under- 
standing of the physiological role of the brain muscarinic receptors, we mapped the distribution of their mRNAs in rat 
brain by in situ hybridization. These mRNAs are barely detectable in the hindbrain and cerebellum. Within forebrain, 
each mRNA has a strikingly different pattern of distribution. The highest levels of ml mRNA are in the cerebral cortex 
and hippocampus followed by the striatum. m3 mRNA is also prominent in the cerebral cortex, but has very low levels 
in the striatum. Conversely, the levels of m4 mRNA are highest in the striatum. Since the cognitive effects of muscarinic 
drugs have been localized to the cerebral cortex and hippocampus, and their psychomotor effects to the striatum, these 
data suggest that the muscarinic receptors which subserve these responses may be different gene products. Finally, we 
show that these muscarinic receptors can be distinguished pharmacologically, suggesting that it may be possible to devel- 
op drugs for the selective treatment of the psychomotor vs cognitive difficulties of Parkinson’s and Alzheimer’s disease, 
respectively. 
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1. INTRODUCTION 
Due to their broad spectrum of action 
muscarinic drugs have been replaced by more 
selective agents in many clinical applications. For 
example, in part because of the peripheral and 
cognitive side-effects induced by antimuscarinic 
agents, they have been largely replaced by 
dopaminergic agents in the treatment of Parkin- 
son’s disease [1,2]. The discovery of heterogeneity 
of muscarinic receptors in binding and functional 
assays has encouraged intensive efforts for the 
development of more selective muscarinic agents. 
Unfortunately, with few exceptions, the classical 
approaches to drug development have met with lit- 
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tle success, possibly due to the limited selectivity of 
the available drugs for putative subtypes, and the 
intimate mixture of multiple subtypes within 
tissues. The most notable exception is the an- 
timuscarinic agent pirenzepine. Pirenzepine has 
high affinity for forebrain and low affinity for 
heart muscarinic receptors, these receptors having 
been designated Ml and M2, respectively [3]. The 
molecular cloning of two muscarinic receptor 
cDNAs, one from porcine brain [4] and the other 
from porcine heart [5,6], has confirmed a struc- 
tural diversity associated with the Ml-M2 
classification, and has illustrated the utility of 
molecular genetics for the study of muscarinic 
receptor heterogeneity. 
Based on the sequence of the brain cDNA we 
recently cloned three cDNAs from rat cerebral cor- 
tex (ml, m3, m4 [7]). Together with the cloned 
heart receptor (m2), these data illustrate the ex- 
istence of four muscarinic receptors with different 
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primary sequences. The human homologs of these 
receptors have also been cloned ([7] and unpublish- 
ed). The ml, m3 and m4 receptors have high af- 
finity for pirenzepine relative to the m2 receptors 
[6-81. Thus, pharmacologically defined Ml 
muscarinic receptors consist of at least three gene 
products designated by lower-case letters (ml, m3, 
m4). To gain insight into the physiological roles of 
these receptors, we localized mRNA encoding 
them within rat brain. Data on the cardiac (m2) 
receptor are not presented here as we have cloned 
the human but not the rat homolog of the m2 
receptor. However, using two 48 base cDNA 
probes, based on the human sequence, we have 
observed RNA with a size of - 6200 bases on Nor- 
thern blots of RNA extracted from rat atria. Using 
these probes we have not detected any RNA on 
Northern blots of RNA extracted from several 
forebrain structures which were positive for ml, 
m3 and m4 RNA (in preparation). 
probes labeled RNA extracted from heart, kidney or liver. In 
RNA extracted from cerebral cortex each probe labeled a single 
mRNA species of 3100, 4500 and 3300 bases for ml, m3 and 
m4, respectively, and their relative levels were ml > m3 > m4. 
2.3. COS cell tramfcctions 
COS-7 cells were transfected with 20 fig plasmid DNA by 
calcium phosphate precipitation [ll]. Cells were plated 24 h 
before transfection (2 x lo6 cells per 10 cm’ plate), media were 
changed 24 h after transfection, and membranes harvested 48 h 
later. The plasmid DNA used for transfections consisted of the 
pcD expression vector which included the SV40 promoter. The 
DNA constructs which encode the muscarinic receptors have 
been described [7]. 
2.4. Binding assays 
Binding assays were adapted from established procedures as 
previously described [12]. Assays were performed in 0.5 ml buf- 
fer [lo mm Hepes, 5 mM MgClz, (pH 7.4)] at room temperature 
with -0.01 mg cos-7 cell membrane protein. Receptors were 
labeled with 100 pM [‘HIQNB and incubated with 10 separate 
concentrations of carbachol for 2 h. The affinities of [‘H]QNB 
for the three populations of binding sites are similar, and have 
been reported [7]. 
2. MATERIALS AND METHODS 3. RESULTS 
2.1. Probes 
We prepared 45 or 48 base oligodeoxynucleotide probes com- 
plementary to sequences encoding amino acids 3-18 (ml), 2-17 
(m3) and 3-17 (m4) of the rat muscarinic receptors [7]. The 
probes were made on an Appied Biosystems DNA synthesizer 
and purified by preparative gel electrophoresis. Each,probe was 
labeled on the 3 ‘-end with terminal deoxynucleotidyl 
transferase and deoxyadenosine triphosphate (labeled in the (Y 
position with ‘*P for Northern blots, > 3000 Ci/mmol, and 35S 
for insitu hybridizations, > 1000 Ci/mmol, New England 
Nuclear). Using a sequencing el we have observed that the 
most common length of our oligonucleotide 3 ‘-tails was 10 
bases. 
2.2. In situ hybridizations 
In situ hybridizations were performed as described for 
localization of G-protein [9] and neuropeptide mRNAs [lo]. 
Briefly, 12 pm sections of rat brain were prepared, mounted on 
gelatin-coated slides and stored at - 70°C until use. Slides were 
warmed to room temperature, acetylated, dehydrated and ex- 
tracted with chloroform. (1-2)x ld dpm of labeled probe was 
added to each section in 50 pl hybridization buffer [4x SSC 
(1xSSC = 0.15 M NaCI, 0.015 M sodium citrate, pH 7.2), 
50% formamide, 1 x Denhardt’s (O.OZcr/o Ficoll, 0.02% 
polyvinylpyrolidone, 0.02% bovine serum albumin), 250 pg/ml 
sheared single-stranded salmon sperm DNA, 100 mM 
dithiothreitol, and 10% dextran sulfate]. Slides were incubated 
overnight in a humid chamber at 37”C, and washed at 55°C 
with 1 x SSC. The slides were dried and exposed to X-ray film 
for 5 weeks. The specificity of each probe was verified on Nor- 
thern blots of total RNA performed under identical stringencies 
to those used for in situ hybridizations [9,10]. None of the 
The distributions of ml, m3 and m4 mRNA in 
coronal (left) and sagittal (right) sections of rat 
brain are illustrated in fig. 1. The concentrations of 
ml and m3 mRNA were highest within the cerebral 
cortex (CX) and hippocampus (H), and within 
these brain regions they displayed distinct patterns 
of distribution. ml mRNA was relatively evenly 
distributed throughout the cerebral cortex, while 
m3 mRNA was present in a more layered pattern. 
Central layers of the cerebral cortex have the 
lowest levels of m3 mRNA. Within the hippocam- 
pus, ml mRNA was abundant within fields CA 
l-3 of Ammon’s horn and the dentate gyrus as il- 
lustrated in the sagittal sections of fig. 1 (fields CA 
l-3 circumscribe the dentate gyrus in the il- 
lustrated sections). m3 mRNA was also abundant 
within fields CA l-3 of Ammon’s horn, but was 
not detected within the dentate gyrus. m4 mRNA 
was present at low levels in the cerebral cortex and 
hippocampus and at high levels within the caudate 
putamen and nucleus accumbens (collectively 
referred to below as the striatum); and olfactory 
tubercle (ventral to the striatum in all illustrated 
sections). ml mRNA was also present in the 
striatum, but at lower levels than those in the 
cerebral cortex and hippocampus. m3 mRNA 
levels were very low in the striatum relative to the 
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Fig. 1. Distribution of muscarinic receptor mRNAs in rat brain. Serial 12 pm coronal (left) and sagittal (right) sections of rat brain 
were hybridized with synthetic ‘?S-labeled oligodeoxynucleotide probes complementary to ml, m3 and m4 mRNA. Sections were 
washed at high stringency and exposed to X-ray film for 5 weeks. Regions rich in mRNA are light in the photomicrographs. 
Nonspecific hybridization was not detectable at this exposure time as defined with probes to mRNAs not expressed in brain (opsin 
and transducin). The illustrated sections correspond to coronal level interaural 10.00 mm and to sagital level lateral 2.90 mm as 
illustrated in the work of Paxinos and Watson [23]. Arrows indicate central ayers of the cerebral cortex, which has little m3 mRNA. 
CX, cerebral cortex; CP, caudate putamen; H, hippocampus. 
cerebral cortex and hippocampus. Overall, these 
data suggest that the majority of muscarinic recep- 
tors in the striatum are different gene products 
from those in the cerebral cortex and hippocam- 
pus. 
Fig.2 illustrates the affinities of the muscarinic 
agonist carbachol for ml, m3 and m4 receptors. 
These receptors were transiently expressed in cos-7 
cells and labeled with 100 pM [3H]QNB. We have 
previously shown that these receptors have similar 
affinities for [‘H]QNB [7]. The affinity of car- 
bachol for the m4 receptor is approx. lo-fold 
higher than for ml and m3 receptors. The I& 
values are 201 ,uM (ml), 125 ,uM (m3) and 10.2pM 
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Fig.2. Binding of carbachol to muscarinic receptors expressed 
in COS-7 cells after transfection with muscarinic receptor 
cDNAs: ml (0), m3 (o), m4 (0). Lines are computer-generated 
best fits of the data to the function 5’0 [‘H]QNB bound = 
1oo-(1ooX/Icso)/(l +x/ICso), where x is carbachol 
concentration. 
(m4). Overall, these data indicate that the 
muscarinic receptors encoded by mRNA which is 
most abundant in the striatum have higher affinity 
for carbachol than those which are most abundant 
in the cerebral cortex and hippocampus. 
4. DISCUSSION 
The composite of the distributions of ml, m3 
and m4 mRNAs is in general agreement with 
previous autoradiographic examinations of 
muscarinic ligand binding to Ml muscarinic recep- 
tors in brain. Ml muscarinic receptors have been 
reported to be abundant in the hippocampus, 
cerebral cortex and striatum, but have low levels in 
the midbrain and hindbrain [ 13,141. Detailed com- 
parisons of receptor and mRNA distributions are 
complicated by several factors including the 
multiplicity of muscarinic receptors and lack of 
knowledge of the relationship of the levels of in- 
dividual receptor mRNA to those of encoded pro- 
tein. Also, unlike receptor proteins which are 
found in all parts of neuronal cells, mRNAs are 
present in cell bodies and proximal dendrites but 
not in distal dendritic fields and terminals which 
may project to different areas of the brain [lo]. 
Muscarinic drugs exert distinct behavioral ef- 
fects which are mediated by the striatum vs the 
cerebral cortex. For example, injection of 
muscarinic agonists in the striatum stimulates 
psychomotor behavior and potentiates the catalep- 
sy induced by dopamine antagonists. Conversely, 
muscarinic antagonists block the catalepsy induced 
by dopamine antagonists [15,16]. In addition to 
playing a role in mediation of psychomotor 
behavior via sites within the striatum, these recep- 
tors are also associated with cognitive function. 
For example, muscarinic agonists improve 
memory and learning [ 171, while antagonists 
disrupt both these forms of behavior [18]. Also, le- 
sions of cholinergic pathways to the cerebral cortex 
and hippocampus disrupt these measures of 
cognitive function and muscarinic agonists reverse 
these lesion-induced deficits, suggesting that 
muscarinic drugs alter cognitive function via sites 
within the cerebral cortex and hippocampus [171. 
In humans, antimuscarinic agents improve the 
psychomotor performance of Parkinson’s patients 
[l] but disrupt their cognitive ability [2]. On the 
other hand, decreases in cholinergic markers have 
been observed in the hippocampi and cerebral cor- 
tices of patients with Alzheimer’s disease, leading 
to the proposal that cholinergic agonists may be 
useful in the treatment of these patients [19-211. It 
is tempting to speculate that if drugs can be 
developed which are selective for the individual 
muscarinic receptor subtypes, they will be useful in 
treating these diseases. That is, an m4 antagonist 
may selectively improve psychomotor perfor- 
mance, and an m3 agonist may selectively improve 
cognitive function. 
While the pharmacological characterization of 
the cloned muscarinic receptors is at a very early 
stage, it is clear that the receptors can be phar- 
macologically distinguished. In addition to car- 
bachol, we have shown that the muscarinic 
antagonist pirenzepine discriminates among these 
receptors. That is, pirenzepine has approx. 4-fold 
lower affinity for m3 than for ml and m4 receptors 
[7]. Pirenzepine and carbachol do not have the 
clinically desired selectivities, as an m3-selective 
agonist and an m6selective antagonist would be 
the most promising candidates for the treatment of 
Alzheimer’s and Parkinson’s disease, respectively, 
The recent establishment of cell lines which stably 
express individual cloned muscarinic receptors 
should accelerate the development of drugs with 
these selectivities [6,12,22]. 
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